新冠疫苗有了新進展

US biotech firm Moderna reported promising early results on Monday from the first clinical tests of an experimental vaccine against the novel coronavirus performed on a small number of volunteers.

美國生物科技公司Moderna週一彙報說，他們對少數志願者進行了新冠病毒實驗性疫苗的首次臨牀測試，初步結果令人鼓舞。

The Cambridge, Massachusetts-based company said the vaccine candidate, mRNA-1273, appeared to produce an immune response in eight people who received it similar to that seen in people convalescing from the virus.

這家位於馬薩諸塞州劍橋市的公司說候選疫苗mRNA-1273在8個接種疫苗的人體內產生了免疫反應，和康復的患者體內的反應差不多。

"These interim Phase 1 data, while early, demonstrate that vaccination with mRNA-1273 elicits an immune response of the magnitude caused by natural infection," said Moderna's chief medical officer Tal Zaks.

Moderna公司首席醫務官Tal Zaks說：“這些暫時獲得的第一階段數據雖然是早期數據，但證明了接種mRNA-1273疫苗會產生和自然感染相同的免疫反應。”

"These data substantiate our belief that mRNA-1273 has the potential to prevent COVID-19 disease and advance our ability to select a dose for pivotal trials," Zaks said.

Zaks說：“這些數據證實了我們的想法，那就是mRNA-1273可以預防新冠肺炎，而且提高了我們選擇關鍵試驗劑量的能力。”

President Donald Trump welcomed the news saying "it's incredible what they can do and I've seen results. "And the results are staggeringly good," Trump told reporters. "So I'm very happy and the market's up very big."

唐納德·特朗普總統聽到這個消息很高興，他說：“他們的能力令人難以置信，我也看到了他們的成績，並且成績喜人。”特朗普對記者說：“所以我很高興，而且市場需求量很大。”

Wall Street stocks posted substantial gains on Monday with the Dow Jones Industrial Average adding 3.85 percent and the S&P 500 up 3.15 percent. Moderna shares gained 19.96 percent to close at US$80.00 in New York.

週一華爾街股市大幅上漲，道瓊斯工業平均指數上漲3.85%，標準普爾500指數上漲3.15%。Moderna公司股票上漲了19.96%，在紐約以80.00美元的價格收盤。

Moderna, which was founded nine years ago, said the vaccine "was generally safe and well tolerated" and that patients suffered no more than redness or soreness from the shots.

九年前成立的Moderna公司稱這種疫苗“總體上很安全、耐受性很好”，接種後只會出現紅腫或疼痛。